Impact of Elexacaftor/Tezacaftor/Ivacaftor on Systemic Antibiotic Utilization in Pediatric Patients With Cystic Fibrosis
Pediatric Pulmonology · 2026-08 · 61 (8)
DOI: 10.1002/ppul.71749 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Pulmonology, online erschienen am 28.07.2026. Verfasst von Julianne Fava und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Nationwide Children's Hospital, Columbus, Ohio, USA. Hauptthemen laut MEDLINE: Cystic Fibrosis, Anti-Bacterial Agents, Indoles, Aminophenols. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, The Ohio State University Center for Clinical and Translational Science (National Center for Advancing Translational Sciences), Cystic Fibrosis Foundation (Research Development Program).
Abstract (Originalsprache)
Introduction
Cystic fibrosis (CF) is an autosomal recessive disease resulting from mutations in the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene. Recurrent respiratory infections are a common problem, and patients receive frequent antibiotics. Treatment of CF involves both symptomatic and underlying disease‐targeting therapies. Elexacaftor/tezacaftor/ivacaftor (ETI), a disease‐targeting therapy, combines two correctors and a potentiator to increase functioning of the CFTR channel. With better functioning channels, symptomatic improvement is expected in the form of decreased respiratory infections.
Objective
To evaluate the change in antibiotic use following the initiation of ETI therapy in pediatric patients.
Methods
This is a single‐center, retrospective chart review conducted at Nationwide Children's Hospital (NCH) in Columbus, Ohio. Patients served as self‐controls, compared before and after initiating ETI. The primary outcome was change in antibiotic days per patient‐year. Secondary outcomes included change in use of specific antibiotics, enteral versus intravenous (IV) therapy, and different classes of antibiotics. The study was approved by the NCH institutional review board (IRB).
Results
The study included 139 patients aged 6–18 years. The median antibiotic days per patient‐year was 17 days pre‐ETI and 6 days post‐ETI ( p < 0.001). There was a significant decrease in antibiotic days per patient‐year for subgroups of IV antibiotics, enteral antibiotics, IV vancomycin, linezolid and tedizolid, anti‐methicillin‐resistant Staphylococcus aureus (MRSA) tetracyclines, other anti‐MRSA medications (clindamycin and trimethoprim/sulfamethoxazole), aminoglycosides, anti‐ Pseudomonas aeruginosa (Psae) beta‐lactams, and fluoroquinolones. There was no significant difference for carbapenems or non‐anti‐Psae beta‐lactams.
Conclusion
ETI therapy was associated with decreased antibiotic days for many therapeutic classes of both enteral and IV antibiotics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Nationwide Children's Hospital, Columbus, Ohio, USA.
- Section of Pulmonary Medicine, Nationwide Children's Hospital, Columbus, Ohio, USA.
- Center for Biostatistics, College of Medicine, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
- Biostatistics Resource at Nationwide Children's Hospital, Abigail Wexner Research Institute and Nationwide Children's Hospital, Columbus, OH, USA.
ORCID-Profile: Julianne Fava, Shahid Sheikh, Mariah Eisner
Förderung
- NCATS NIH HHS
- The Ohio State University Center for Clinical and Translational Science (National Center for Advancing Translational Sciences)
- Cystic Fibrosis Foundation (Research Development Program)
- Cure CF Columbus Translational Core (C3TC) supported by the Division of Pediatric Pulmonary Medicine, the Biopathology Center Core, and the Data Collaboration…
- National Center for Advancing Translational Sciences
Zitieren
APA
Fava, J., Stephan, E., Tansmore, J., Sheikh, S., Eisner, M., & Novak, K. J. (2026). Impact of Elexacaftor/Tezacaftor/Ivacaftor on Systemic Antibiotic Utilization in Pediatric Patients With Cystic Fibrosis. Pediatric Pulmonology, 61(8). https://doi.org/10.1002/ppul.71749
Vancouver
Fava J, Stephan E, Tansmore J, Sheikh S, Eisner M, Novak KJ. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Systemic Antibiotic Utilization in Pediatric Patients With Cystic Fibrosis. Pediatric Pulmonology. 2026;61(8). doi:10.1002/ppul.71749
BibTeX
@article{Fava2026,
author = {Fava, Julianne and Stephan, Emily and Tansmore, Jessica and Sheikh, Shahid and Eisner, Mariah and Novak, Kimberly J},
title = {Impact of Elexacaftor/Tezacaftor/Ivacaftor on Systemic Antibiotic Utilization in Pediatric Patients With Cystic Fibrosis},
journal = {Pediatric Pulmonology},
year = {2026},
volume = {61},
number = {8},
doi = {10.1002/ppul.71749}
}
EUVIMED